Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes

Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-analysis

Research output: Contribution to journal › Review › Research › peer-review

Standard

Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes : A Systematic Review and Meta-analysis. / Gubatan, John; Barber, Grant E.; Nielsen, Ole Haagen; Juhl, Carsten Bogh; Maxwell, Cynthia; Eisenberg, Michael L.; Streett, Sarah E.

In: Clinical Gastroenterology and Hepatology, Vol. 21, No. 9, 2023, p. 2222-2238.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Gubatan, J, Barber, GE, Nielsen, OH, Juhl, CB, Maxwell, C, Eisenberg, ML & Streett, SE 2023, 'Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-analysis', Clinical Gastroenterology and Hepatology, vol. 21, no. 9, pp. 2222-2238. https://doi.org/10.1016/j.cgh.2022.07.008

APA

Gubatan, J., Barber, G. E., Nielsen, O. H., Juhl, C. B., Maxwell, C., Eisenberg, M. L., & Streett, S. E. (2023). Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 21(9), 2222-2238. https://doi.org/10.1016/j.cgh.2022.07.008

Vancouver

Gubatan J, Barber GE, Nielsen OH, Juhl CB, Maxwell C, Eisenberg ML et al. Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2023;21(9):2222-2238. https://doi.org/10.1016/j.cgh.2022.07.008

Author

Gubatan, John ; Barber, Grant E. ; Nielsen, Ole Haagen ; Juhl, Carsten Bogh ; Maxwell, Cynthia ; Eisenberg, Michael L. ; Streett, Sarah E. / Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes : A Systematic Review and Meta-analysis. In: Clinical Gastroenterology and Hepatology. 2023 ; Vol. 21, No. 9. pp. 2222-2238.

Bibtex

@article{24febef6d1e0441596245fa35b9b4887,

title = "Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-analysis",

abstract = "BACKGROUND & AIMS: Studies evaluating reproductive outcomes among male patients with inflammatory bowel disease (IBD) are limited. We evaluated use of IBD medications and association with semen parameters, a proxy of male fertility, and adverse pregnancy outcomes (early pregnancy loss [EPL], preterm birth [PB], congenital malformations [CM]).METHODS: We searched Medline, Embase, Scopus, and Web of Science (PROSPERO CRD42020197098) from inception to April 2022 for studies reporting semen parameters and adverse pregnancy outcomes among male patients exposed to biologics, thiopurine, or methotrexate. Standardized mean difference, prevalence, and odds ratios (ORs) of outcomes were pooled and analyzed using a random effects model.RESULTS: Ten studies reporting semen parameters (268 patients with IBD) and 16 studies reporting adverse pregnancy outcomes (over 25,000 patients with IBD) were included. Biologic, thiopurine, or methotrexate use were not associated with decreased sperm count, motility, or abnormal morphology compared with nonexposed patients. The prevalence of adverse pregnancy outcomes with paternal biologic (5%), thiopurine (6%), or methotrexate (6%) exposure was comparable to nonexposed patients (5%). Biologic use was not associated with risk of EPL (OR, 1.26; I2 = 0%; P = .12), PB (OR, 1.10; I2 = 0%; P = .17), or CM (OR, 1.03; I2 = 0%; P = .69). Thiopurine use was not associated with risk of EPL (OR, 1.31; I2 = 19%; P = .17), PB (OR, 1.05; I2 = 0%; P = .20), or CM (OR, 1.07; I2 = 7%; P = .34). Methotrexate use was not associated with risk of PB (OR, 1.06; I2 = 0%; P = .62) or CM (OR, 1.03; I2 = 0%; P = .81).CONCLUSIONS: Biologic, thiopurine, or methotrexate use among male patients with IBD are not associated with impairments in fertility or with increased odds of adverse pregnancy outcomes.",

author = "John Gubatan and Barber, {Grant E.} and Nielsen, {Ole Haagen} and Juhl, {Carsten Bogh} and Cynthia Maxwell and Eisenberg, {Michael L.} and Streett, {Sarah E}",

year = "2023",

doi = "10.1016/j.cgh.2022.07.008",

language = "English",

volume = "21",

pages = "2222--2238",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B.Saunders Co.",

number = "9",

}

RIS

TY - JOUR

T1 - Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes

T2 - A Systematic Review and Meta-analysis

AU - Gubatan, John

AU - Barber, Grant E.

AU - Nielsen, Ole Haagen

AU - Juhl, Carsten Bogh

AU - Maxwell, Cynthia

AU - Eisenberg, Michael L.

AU - Streett, Sarah E

PY - 2023

Y1 - 2023

N2 - BACKGROUND & AIMS: Studies evaluating reproductive outcomes among male patients with inflammatory bowel disease (IBD) are limited. We evaluated use of IBD medications and association with semen parameters, a proxy of male fertility, and adverse pregnancy outcomes (early pregnancy loss [EPL], preterm birth [PB], congenital malformations [CM]).METHODS: We searched Medline, Embase, Scopus, and Web of Science (PROSPERO CRD42020197098) from inception to April 2022 for studies reporting semen parameters and adverse pregnancy outcomes among male patients exposed to biologics, thiopurine, or methotrexate. Standardized mean difference, prevalence, and odds ratios (ORs) of outcomes were pooled and analyzed using a random effects model.RESULTS: Ten studies reporting semen parameters (268 patients with IBD) and 16 studies reporting adverse pregnancy outcomes (over 25,000 patients with IBD) were included. Biologic, thiopurine, or methotrexate use were not associated with decreased sperm count, motility, or abnormal morphology compared with nonexposed patients. The prevalence of adverse pregnancy outcomes with paternal biologic (5%), thiopurine (6%), or methotrexate (6%) exposure was comparable to nonexposed patients (5%). Biologic use was not associated with risk of EPL (OR, 1.26; I2 = 0%; P = .12), PB (OR, 1.10; I2 = 0%; P = .17), or CM (OR, 1.03; I2 = 0%; P = .69). Thiopurine use was not associated with risk of EPL (OR, 1.31; I2 = 19%; P = .17), PB (OR, 1.05; I2 = 0%; P = .20), or CM (OR, 1.07; I2 = 7%; P = .34). Methotrexate use was not associated with risk of PB (OR, 1.06; I2 = 0%; P = .62) or CM (OR, 1.03; I2 = 0%; P = .81).CONCLUSIONS: Biologic, thiopurine, or methotrexate use among male patients with IBD are not associated with impairments in fertility or with increased odds of adverse pregnancy outcomes.

AB - BACKGROUND & AIMS: Studies evaluating reproductive outcomes among male patients with inflammatory bowel disease (IBD) are limited. We evaluated use of IBD medications and association with semen parameters, a proxy of male fertility, and adverse pregnancy outcomes (early pregnancy loss [EPL], preterm birth [PB], congenital malformations [CM]).METHODS: We searched Medline, Embase, Scopus, and Web of Science (PROSPERO CRD42020197098) from inception to April 2022 for studies reporting semen parameters and adverse pregnancy outcomes among male patients exposed to biologics, thiopurine, or methotrexate. Standardized mean difference, prevalence, and odds ratios (ORs) of outcomes were pooled and analyzed using a random effects model.RESULTS: Ten studies reporting semen parameters (268 patients with IBD) and 16 studies reporting adverse pregnancy outcomes (over 25,000 patients with IBD) were included. Biologic, thiopurine, or methotrexate use were not associated with decreased sperm count, motility, or abnormal morphology compared with nonexposed patients. The prevalence of adverse pregnancy outcomes with paternal biologic (5%), thiopurine (6%), or methotrexate (6%) exposure was comparable to nonexposed patients (5%). Biologic use was not associated with risk of EPL (OR, 1.26; I2 = 0%; P = .12), PB (OR, 1.10; I2 = 0%; P = .17), or CM (OR, 1.03; I2 = 0%; P = .69). Thiopurine use was not associated with risk of EPL (OR, 1.31; I2 = 19%; P = .17), PB (OR, 1.05; I2 = 0%; P = .20), or CM (OR, 1.07; I2 = 7%; P = .34). Methotrexate use was not associated with risk of PB (OR, 1.06; I2 = 0%; P = .62) or CM (OR, 1.03; I2 = 0%; P = .81).CONCLUSIONS: Biologic, thiopurine, or methotrexate use among male patients with IBD are not associated with impairments in fertility or with increased odds of adverse pregnancy outcomes.

U2 - 10.1016/j.cgh.2022.07.008

DO - 10.1016/j.cgh.2022.07.008

M3 - Review

C2 - 35870769

VL - 21

SP - 2222

EP - 2238

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 9

ER -

ID: 345430522